Evidence map›Paper›PMID 39934790›Full record

ArticleBMC biology2025

Delivering miR-23b-3p by small extracellular vesicles to promote cell senescence and aberrant lipid metabolism.

Ye Jin, Gaoge Sun, Binxian Chen, Siqin Feng, Muyun Tang, Hui Wang, Ying Zhang, Yuan Wang, Yang An, Yu Xiao and 6 more

Abstract read
In one paragraph

Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ye Jin *Rare Disease Medical Center, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, 100730, China.
Gaoge Sun *School of Pharmaceutical Sciences, Tsinghua University, Beijing, 100084, China.
Binxian Chen *Rare Disease Medical Center, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, 100730, China.
Siqin Feng *Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, 100730, China.
Muyun Tang *Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, 100730, China.
Hui WangDepartment of Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, 100730, China.
Ying ZhangSchool of Pharmaceutical Sciences, Tsinghua University, Beijing, 100084, China.
Yuan WangEcho Biotech Co., Ltd, Beijing, 102627, China.
Yang AnGemPharmatech Co., Ltd, Nanjing, 210000, China.
Yu XiaoSchool of Pharmaceutical Sciences, Tsinghua University, Beijing, 100084, China.
Zihan LiuSchool of Pharmaceutical Sciences, Tsinghua University, Beijing, 100084, China.
Peng LiuMedical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, 100730, China.
Zhuang TianDepartment of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, 100730, China. tianzhuangcn@sina.com.
Hang YinSchool of Pharmaceutical Sciences, Tsinghua University, Beijing, 100084, China. yin_hang@tsinghua.edu.cn.
Shuyang ZhangRare Disease Medical Center, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, 100730, China. shuyangzhang103@nrdrs.org.
Xiaodong LuanRare Disease Medical Center, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, 100730, China. luanxiaodong@pumch.cn.

Funding

14th Five-Year Key Research and Development Plan, Ministry of Science and Technology 2022YFC2703100Beijing Advanced Innovation Center for Structural Biology, Tsinghua University 20151551402Beijing Outstanding Young Scientist Program BJJWZYJH01201910003013CAMS Innovation Fund for Medical Sciences 2021-CAMS-JZ004Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences 2021-I2M-1-003National High Level Hospital Clinical Research Funding 2022-PUMCH-B-098National High Level Hospital Clinical Research Funding 2022-PUMCH-D-002National Natural Science Foundation of China 21825702National Natural Science Foundation of China 22137004National Natural Science Foundation of China 82170486Tsinghua-Peking Center for Life Sciences 045-61020100123
6 · The paper itself

Abstract

backgroundAging is a natural process that affects the majority of organs within the organism. The liver, however, plays a pivotal role in maintaining the organism's homeostasis due to its robust regenerative and metabolic capabilities. Nevertheless, the liver also undergoes the effects of aging, which can result in a range of metabolic disorders. The function of extracellular vesicles and the signals they convey represent a significant area of interest within the field of ageing research. However, research on liver ageing from the perspective of EVs remains relatively limited.

resultsIn the present study, we extracted liver tissue small extracellular vesicles (sEVs) of mice at different ages and performed transcriptome and proteome analyses to investigate the senescence-associated secretory phenotype (SASP) and mechanisms. sEVs in the older group were rich in miR-23b-3p, which was abundant in the sEVs of induced aging cells and promoted cell senescence by targeting TNF alpha induced protein 3 (Tnfaip3). After injecting adeno-associated virus (AAV) expressing miR-23b-3p into mice, the liver of mice in the experimental group displayed a more evident inflammatory response than that in the control group. Additionally, we found elevated miR-23b-3p in blood-derived-sEVs from patients with familial hypercholesterolemia.

conclusionsOur findings suggest that miR-23b-3p plays a pivotal role in liver aging and is associated with abnormal lipid metabolism. The upregulation of miR-23b-3p in liver EVs may serve as a potential biomarker for aging and metabolic disorders. Targeting miR-23b-3p could provide new therapeutic strategies for ameliorating age-related liver dysfunction and associated metabolic abnormalities.

Indexed as

Cellular SenescenceExtracellular VesiclesLipid MetabolismMicroRNAsAnimalsHumansLiverMaleMiceMice, Inbred C57BLMicroRNAsMirn23b microRNA, mouseAgingFamilial hypercholesterolemiaLipid metabolismmiR-23b-3psEV

Identifiers

PMID39934790
PMCPMC11817603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.